Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and safety of bosutinib 500 mg/d (n = 250) versus imatinib 400 mg/d (n = 252) after >24 months from accrual completion in newly diagnosed chronic phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Brümmendorf, Tim H, Cortes, Jorge E, de Souza, Cármino Antonio, Guilhot, Francois, Duvillié, Ladan, Pavlov, Dmitri, Gogat, Karïn, Countouriotis, Athena M, Gambacorti-Passerini, Carlo
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2015
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4274978/
https://ncbi.nlm.nih.gov/pubmed/25196702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13108
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados